mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Diabetic nephropathy (DN) is among the most lethal complications that occur in type 1 and type 2 diabetics. Podocyte dysfunction is postulated to be a critical event associated with proteinuria and glomerulosclerosis in glomerular diseases including DN. However, molecular mechanisms of podocyte dysfunction in the development of DN are not well understood. Here we have shown that activity of mTOR complex 1 (mTORC1), a kinase that senses nutrient availability, was enhanced in the podocytes of diabetic animals. Further, podocyte-specific mTORC1 activation induced by ablation of an upstream negative regulator (PcKOTsc1) recapitulated many DN features, including podocyte loss, glomerular basement membrane thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice. Abnormal mTORC1 activation caused mislocalization of slit diaphragm proteins and induced an epithelial-mesenchymal transition-like phenotypic switch with enhanced ER stress in podocytes. Conversely, reduction of ER stress with a chemical chaperone significantly protected against both the podocyte phenotypic switch and podocyte loss in PcKOTsc1 mice. Finally, genetic reduction of podocyte-specific mTORC1 in diabetic animals suppressed the development of DN. These results indicate that mTORC1 activation in podocytes is a critical event in inducing DN and suggest that reduction of podocyte mTORC1 activity is a potential therapeutic strategy to prevent DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ulianich, L., Garbi, C., Treglia, A. S., Punzi, D., Miele, C., Raciti, G. A., Bèguinot, F., Consiglio, E., & Jeso, B. D. (2008) · Journal of Cell Science · doi:10.1242/jcs.017202 · Cited by 114
RetractedTOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Self-citationKestilä, M., Lenkkeri, U., Männikkö, M., Lamerdin, J., McCready, P., Putaala, H., Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R., et al. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80057-x · Cited by 1,866
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., Dahan, K., Gubler, M.-C., Niaudet, P., & Antignac, C. (2000) · Nature Genetics · doi:10.1038/74166 · Cited by 1,444
Research works printed but not linked: 2
- Zhong, Am J Respir Cell Mol Biol.
- Kouraklis, 2006, Oncol Rep., 15, 489
Cited by
Items 201–300 of 544
Zheng, X.-P., Qing, N., Feng, J., Fan, X., Jin, Y., Chen, G., & Du, J. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01833-6 · Cited by 54
Chen, N., Mu, L., Yang, Z., Du, C., Wu, M. T., Song, S., Yuan, C., & Shi, Y. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29890 · Cited by 53
“In the diabetic animal model, a decrease in specific mTORC1 activity ameliorated the pathogenesis of DN (Inoki et al., 2011; Lloberas et al., 2006).”
BackgroundModes of podocyte death in diabetic kidney disease: an update
Jiang, A., Song, A., & Zhang, C. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01269-1 · Cited by 51
“As a key event in DKD induction, overactivation of mTORC1 stimulates ERS and EMT-like phenotypes in podocytes, ultimately leading to podocyte anoikis [95].”
BackgroundTherapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“Briefly, these studies make use of two distinct models to show that mTORC1 overactivation in nondiabetic mice caused a glomerular disease closely resembling DN, while podocytespecific inhibition of mTORC1 activity protected mice from DN development [58, 143].”
BackgroundResultThe role of local IL6/JAK2/STAT3 signaling in high glucose–induced podocyte hypertrophy
Jo, H. A., Kim, J., Yang, S. H., Han, S. S., Joo, K. W., Kim, Y. S., & Kim, D. K. (2016) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2016.09.003 · Cited by 48
The Importance of Autophagy in Cardioprotection
Sciarretta, S., Yee, D., Shenoy, V., Nagarajan, N., & Sadoshima, J. (2013) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-013-0029-9 · Cited by 48
Signaling Mechanisms in the Regulation of Renal Matrix Metabolism in Diabetes
Mariappan, M. M. (2012) · Experimental Diabetes Research · doi:10.1155/2012/749812 · Cited by 50
“[67] shows that genetic reduction of mTORC1 activity by eliminating 1 Raptor allele prevents podocyte injury and ameliorates the progression of common glomerular diseases such as diabetic nephropathy; mTORC1 activation induced by ablation of an upstream negative regulator Tsc1 recapitulated many DN features, including…”
BackgroundDas, R., Xu, S., Nguyen, T. T., Quan, X., Choi, S.-K., Kim, S., Lee, E. Y., Cha, S., & Park, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.703116 · Cited by 51
“Recent evidence has shown that mammalian target of rapamycin (mTOR)(3) signaling activation is an important mediator of diabetic nephropathy in mice and humans (5, 6).”
Liu, P., Yang, X. C., Hei, C., Meli, Y., Niu, J., Sun, T., & Li, P. A. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15624 · Cited by 48
Kumar, V., Wollner, C., Kurth, T., Bukowy, J., & Cowley, A. (2017) · HYPERTENSION · doi:10.1161/hypertensionaha.117.09456 · Cited by 37
Glucose Transporters in Diabetic Kidney Disease—Friends or Foes?
Wasik, A. A., & Lehtonen, S. H. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00155 · Cited by 50
“Hyperactivation of the mTORC1 signal is strongly associated with the progression of podocyte injury and proteinuria in diabetic animal models, characterized by dysregulation of nephrin and podocyte loss (39, 81).”
BackgroundHolderied, A., Romoli, S., Eberhard, J. N., Konrad, L., Devarapu, S. K., Marschner, J. A., Müller, S., & Anders, H. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.160 · Cited by 46
Guo, W., Qiu, W., Ao, X., Li, W., He, X., Ao, L., Hu, X., Li, Z., Zhu, M., Luo, D., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15052 · Cited by 52
“…is activated in diabetic liver, heart and kidney tissue. mTORC1 hyperactivation is a key determinant for the development of diabetic nephropathy (Godel et al., 2011; Inoki et al., 2011), diabetic cardiomyopathy and hepatic insulin resistance (Korsheninnikova et al., 2006; Volkers et al., 2014).”
BackgroundMicroRNAs in Podocyte Injury in Diabetic Nephropathy
Ishii, H., Kaneko, S., Yanai, K., Aomatsu, A., Hirai, K., Ookawara, S., Ishibashi, K., & Morishita, Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00993 · Cited by 48
“For example, recent studies have shown that mTOR complex1 (mTORC1) activity is increased in podocytes in diabetic nephropathy (Godel et al., 2011; Inoki et al., 2011).”
Essential Role of X-Box Binding Protein-1 during Endoplasmic Reticulum Stress in Podocytes
Hassan, H., Tian, X., Inoue, K., Chai, N., Liu, C., Soda, K., Moeckel, G. W., Tufró, A., Lee, A.-H., Somlo, S., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015020191 · Cited by 46
The insulin receptor and the kidney
Hale, L. J., & Coward, R. J. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835abb52 · Cited by 45
“Moreover, and similar to other molecules such as vascular endothelial growth factor-A [42,43], overactivity of the mTOR complex, specifically mTORC1, also results in glomerular disease [40] (this may be particularly important in diabetic nephropathy).”
BackgroundRapamycin Reduces Podocyte Apoptosis and is Involved in Autophagy and mTOR/ P70S6K/4EBP1 Signaling
Jin, J., Hu, K. Q., Ye, M., Wu, D., & He, Q. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491905 · Cited by 45
Insulin signalling to the kidney in health and disease
Hale, L. J., & Coward, R. J. (2012) · Clinical Science · doi:10.1042/cs20120378 · Cited by 46
Dey, N., Bera, A., Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., & Choudhury, G. G. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.03.007 · Cited by 44
Autophagy in Chronic Kidney Diseases
Liu, N., Shi, Y., & Zhuang, S. (2016) · Kidney Diseases · doi:10.1159/000444841 · Cited by 45
Zhang, H., Wang, W., Ren, L.-H., Zhao, X.-X., Wang, Z., Zhuang, D.-L., & Bai, Y.-N. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453163 · Cited by 44
Kim, Y., Park, S.-J., & Chen, Y. M. (2017) · Translational research · doi:10.1016/j.trsl.2017.06.010 · Cited by 53
Perspectives on the role of PTEN in diabetic nephropathy: an update
Khokhar, M., Roy, D., Modi, A., Agarwal, R. G., Yadav, D., Purohit, P., & Sharma, P. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1746735 · Cited by 44
MicroRNAs and their delivery in diabetic fibrosis
Wonnacott, A., Denby, L., Coward, R. J., Fraser, D. J., & Bowen, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114045 · Cited by 45
KLF15 Is a Molecular Link between Endoplasmic Reticulum Stress and Insulin Resistance
Jung, D. Y., Chalasani, U., Pan, N., Friedline, R. H., Prosdocimo, D. A., Nam, M., Azuma, Y., Maganti, R. J., Yu, K. M., Velagapudi, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077851 · Cited by 49
“An important energysparing function of activated AMPK is to reduce protein translation by inhibiting mTORC1 [30].”
BackgroundAutophagy in renal tubular injury and repair
Lin, F. (2017) · Acta Physiologica · doi:10.1111/apha.12852 · Cited by 44
“…John Wiley & Sons Ltd, doi: 10.1111/apha.12852232 physiological and pathological conditions in glomerular and interstitial compartments (Hartleben et al. 2010, Godel et al. 2011, Inoki et al. 2011, Cina et al. 2012, Bechtel et al. 2013, Chen et al. 2013, Kawakami et al. 2015, Lenoir et al. 2016).”
BackgroundInfluentialKarunasagara, S., Hong, G.-L., Park, S.-R., Lee, N., Jung, D.-Y., Kim, T., & Jung, J. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112693 · Cited by 46
Sávio-Silva, C., Soinski-Sousa, P. E., Simplício-Filho, A., Bastos, R. M. C., Beyerstedt, S., & Rangel, É. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041546 · Cited by 44
Relationship of glucose and oleate metabolism to cardiac function in lipin-1 deficient (fld) mice
Kok, B. P., Kienesberger, P. C., Dyck, J. R. B., & Brindley, D. N. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m019430 · Cited by 45
New players in the pathogenesis of focal segmental glomerulosclerosis
Schell, C., & Huber, T. B. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs273 · Cited by 44
“could now dissect the role of the mTOR complexes in podocyte maintenance and disease [52, 53].”
BackgroundSelf-citationDenhez, B., Rousseau, M., Spino, C., Dancosst, D.-A., Dumas, M.-È., Guay, A., Lizotte, F., & Geraldes, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-78376-1 · Cited by 212
Gondaliya, P., Dasare, A. P., Jash, K., Tekade, R. K., Srivastava, A., & Kalia, K. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-019-00469-0 · Cited by 43
“Podocin is a podocyte-specific marker which is another slit diaphragm protein found to be downregulated in DN conditions [32].”
BackgroundNQO1 protects obese mice through improvements in glucose and lipid metabolism
Francesco, A. D., Choi, Y., Bernier, M., Zhang, Y., Díaz‐Ruiz, A., Aon, M. A., Kalafut, K. C., Ehrlich, M. R., Murt, K. N., Ali, A., et al. (2020) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-020-00051-6 · Cited by 44
Luo, Q., Liang, W., Zhang, Z., Zhu, Z., Chen, Z., Hu, J., Yang, K., Chi, Q., & Ding, G. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155245 · Cited by 43
Borsting, E., Patel, S. V., Declèves, A., Lee, S. J., Rahman, Q. M., Akira, S., Satriano, J. A., Sharma, K., Vallon, V., & Cunard, R. A. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013070811 · Cited by 42
Energy restriction in renal protection
Wang, S., Cai, G., & Chen, X. (2018) · British Journal Of Nutrition · doi:10.1017/s0007114518002684 · Cited by 42
“The mTOR signalling pathway is associated with DN and polycystic kidney disease((91,92)).”
BackgroundNistala, R., & Whaley‐Connell, A. T. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.02.005 · Cited by 39
Mammalian target of rapamycin signaling in the podocyte
Inoki, K., & Huber, T. B. (2012) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e3283520f38 · Cited by 38
Self-citationKim, J., Wilbon, S. S., & Fornoni, A. (2021) · Kidney360 · doi:10.34067/kid.0006152020 · Cited by 40
Transforming growth factor-beta and the glomerular filtration barrier
Ghayur, A., & Margetts, P. J. (2013) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2013.01.003 · Cited by 38
“Other pathways shown to be involved in podocyte EMT include mammalian target of rapamycin (mTOR) [68,69], glycogen synthase kinase 3 b (GSK3B) [70], b -catenin [71], integrin-linked kinase (ILK) [72], and Notch [73].”
BackgroundRistola, M., & Lehtonen, S. H. (2013) · Clinical Science · doi:10.1042/cs20130258 · Cited by 42
Type 2 diabetes – unmet need, unresolved pathogenesis, mTORC1-centric paradigm
Bar‐Tana, J. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09545-w · Cited by 44
Teh, Y. M., Mualif, S. A., & Lim, S. K. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106153 · Cited by 40
Das, F., Bera, A., Ghosh‐Choudhury, N., Abboud, H. E., Kasinath, B. S., & Choudhury, G. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109608 · Cited by 40
“Recently, we and others have shown that in diabetic kidney disease in which TGFb plays a significant role to produce extracellular matrix, administration of rapamycin, which inhibits both mTORC1 and mTORC2 in mice, resulted in marked reduction in matrix proteins including collagen I (a2) [33,34,55,56].”
BackgroundLooking at the (w)hole: magnet resonance imaging in polycystic kidney disease
Liebau, M. C., & Serra, A. L. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2370-y · Cited by 41
“glomerular podocytes [85–88].”
Kim, D. K., Nam, B. Y., Li, J. J., Park, J. T., Lee, S. H., Kim, D., Kim, J. Y., Kang, H. Y., Han, S. H., Yoo, T., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2467-7 · Cited by 37
“However, recent studies have shown that mTORC1 effectors are upregulated in the podocytes of diabetic glomeruli, and podocytespecific mTORC1 inhibition attenuates not only diabetesinduced podocyte hypertrophy but also glomerulosclerosis [10, 34].”
BackgroundMesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy
Paulini, J., Higuti, E., Bastos, R. M. C., Gomes, S. A., & Rangel, É. B. (2016) · Stem Cells International · doi:10.1155/2016/9521629 · Cited by 40
“Furthermore, abnormal mTORC1 activation causes mislocalization of slit diaphragm proteins and induces an epithelial-mesenchymal transition-like phenotypic switch with enhanced endoplasmic reticulum (ER) stress [100].”
The function of endocytosis in podocytes
Soda, K., & Ishibe, S. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283624820 · Cited by 37
“The functional and ultrastructural changes produced by the lack of dynamin and synaptojanin 1 or endophilin were strikingly similar [28].”
BackgroundLü, Q., Chen, Y., Yang, H., Wang, W.-W., Li, C., Wang, L., Wang, J., Du, L., & Yin, X. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0244-6 · Cited by 39
Self-citationXu, L., You, Y., Wang, J., Qin, Y., Huang, P., & Yang, F. (2014) · Inflammation · doi:10.1007/s10753-014-9961-7 · Cited by 36
Self-citationLei, J., Zhao, L., Zhang, Y., Wu, Y., & Liu, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488231 · Cited by 36
Activation of mTORC1 in Collecting Ducts Causes Hyperkalemia
Chen, Z., Dong, H., Jia, C., Song, Q., Chen, J., Zhang, Y., Lai, P., Fan, X., Zhou, X., Liu, M., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013030225 · Cited by 35
PACSIN2 accelerates nephrin trafficking and is up‐regulated in diabetic kidney disease
Dumont, V., Tolvanen, T. A., Kuusela, S., Wang, H., Nyman, T. A., Lindfors, S., Tienari, J., Nísen, H., Suetsugu, S., Plomann, M., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201601265r · Cited by 39
“In DKD models, nephrin often appears to be downregulated (7, 8) ormislocalized (9).”
BackgroundNovel Actions of Growth Hormone in Podocytes: Implications for Diabetic Nephropathy
Mukhi, D., Nishad, R., Menon, R. K., & Pasupulati, A. K. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00102 · Cited by 36
“Constitutive activation of mTORC1 recapitulated several DN features including podocyte hypertrophy, proteinuria, and glomerular sclerosis (92).”
BackgroundChen, F., Le, S., Zhou, T., Li, Y., Loveless, R., Li, H., Teng, Y., & Cai, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02681-6 · Cited by 38
IRS2 and PTEN are key molecules in controlling insulin sensitivity in podocytes
Santamaría, B., Márquez, E., Lay, A. C., Carew, R. M., González‐Rodríguez, Á., Welsh, G. I., Ni, L., Hale, L. J., Ortíz, A., Saleem, M. A., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.09.020 · Cited by 36
“Similarly, differing roles of mTORC1 between the glomeruli and tubules in DN have also been reported [53,54].”
BackgroundCrucial genes associated with diabetic nephropathy explored by microarray analysis
Wang, Z., Wang, Z., Zhou, Z., & Ren, Y. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0343-2 · Cited by 36
“For example, the mammalian target of rapamycin (mTOR) complex 1 activation has a key role in podocyte dysfunction in diabetic mice [3, 4].”
BackgroundReifsnyder, P. C., Flurkey, K., Doty, R. A., Calcutt, N. A., Koza, R. A., & Harrison, D. E. (2022) · Aging Cell · doi:10.1111/acel.13666 · Cited by 37
“Suppression of diabetic nephropathy by direct inhibition of mTORC1 in the podocyte of the nephron (Inoki et al., 2011) provides a direct mechanism for the RAPA- mediated protection.”
BackgroundGarg, P. K., & Holzman, L. B. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.02.030 · Cited by 37
Self-citationAutophagy and metabolic changes in obesity-related chronic kidney disease
Satriano, J. A., & Sharma, K. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft229 · Cited by 34
“[63] hyper-activated podocyte selective mTORC1 in mice and observed podocyte damage and glomerular lesions similar to the diabetic phenotype, including proteinuria and mesangial expansion.”
BackgroundEnhanced insulin receptor, but not PI3K, signalling protects podocytes from ER stress
Garner, K., Betin, V. M. S., Pinto, V., Graham, M., Abgueguen, E., Barnes, M., Bedford, D. C., McArdle, C. A., & Coward, R. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-22233-9 · Cited by 34
Kuwagata, S., Kume, S., Chin‒Kanasaki, M., Araki, H., Araki, S., Nakazawa, J., Sugaya, T., Koya, D., Haneda, M., Maegawa, H., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.06.036 · Cited by 33
Song, S., Qiu, D., Shi, Y., Wang, S., Zhou, X., Chen, N., Wei, J., Wu, M. T., Wu, H., & Duan, H. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28317 · Cited by 35
“It has been documented that mTOR is involved in DN (Eid et al., 2013; Godel et al., 2011; Inoki et al., 2011), and the activation of mTOR pathway is associated with TXNIP (Huang et al., 2014).”
BackgroundInfluentialJin, J., Gong, J., Zhao, L., Zhang, H., He, Q., & Jiang, X. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12914 · Cited by 33
“Once mTOR signaling is activated, the production of the autophagosome is inhibited by activation of UNC-51-like kinase 1 (ULK1).8 Blockade of autophagosome generation subsequently blunts the protective role of autophagy against podocyte damage.9 In addition, upregulation of mTOR activity that can inhibit autophagy lea…”
BackgroundInfluentialSGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Safaie, N., Masoumi, S., Alizadeh, S., Mirzajanzadeh, P., Nejabati, H. R., Hajiabbasi, M., Alivirdiloo, V., Basmenji, N. C., Radvar, A. D., Majidi, Z., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3922 · Cited by 38
“70 The mechanism of SGLT2 inhibitors is related to reducing the activity of mTORC1.”
BackgroundMinakawa, A., Fukuda, A., Sato, Y., Kikuchi, M., Kitamura, K., Wiggins, R. C., & Fujimoto, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-54692-z · Cited by 32
Self-citationDevelopment of Biomarkers and Molecular Therapy Based on Inflammatory Genes in Diabetic Nephropathy
Maiti, A. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189985 · Cited by 33
“Excessive mTORC1 inhibition also led to podocyte dysfunction [61].”
BackgroundComplement factor B in high glucose–induced podocyte injury and diabetic kidney disease
Lu, Q., Hou, Q., Cao, K., Sun, X., Liang, Y., Gu, M., Xue, X., Zhao, A. Z., & Dai, C. (2021) · JCI Insight · doi:10.1172/jci.insight.147716 · Cited by 34
mTOR inhibitors and renal allograft: Yin and Yang
Zaza, G., Granata, S., Tomei, P., Masola, V., Gambaro, G., & Lupo, A. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0103-y · Cited by 32
“Numerous experimental data have shown that mTOR-I may interfere with the protein endocytosis in the tubular epithelial cells [67], podocytes homeostasis [68, 69] and VEGF secretion and activity.”
BackgroundChinese Herbal Medicine in Ameliorating Diabetic Kidney Disease via Activating Autophagy
Wang, Y., Zhao, H., Wang, Q., Zhou, X., Lu, X., Liu, T., Zhan, Y., & Li, P. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9030893 · Cited by 33
“Podocyte-specific mTORC1 activation in mice by knocking out TSC1 results in significant proteinuria and glomerulopathy under both diabetic and nondiabetic conditions, paralleled by glomerular hypertrophy; mesangial expansion; and decreased number of podocytes and phenotypic change [31].”
BackgroundWang, T., Gao, Y., Yue, R., Wang, X., Shi, Y., Xu, J., Wu, B., & Li, Y. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2735714 · Cited by 42
“/emTOR pathway has been previously implicated in podocyte injury [47] and was also upregulated in the affected cells in our study.”
BackgroundHinden, L., Ahmad, M., Hamad, S., Nemirovski, A., Szanda, G., Glasmacher, S., Kogot‐Levin, A., Abramovitch, R., Thorens, B., Gertsch, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29124-8 · Cited by 32
Targeted inhibition of endoplasmic reticulum stress: New hope for renal fibrosis
Ke, B., Zhu, N., Luo, F., Xu, Y., & Fang, X. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6762 · Cited by 31
“Moreover, the activation of rapamycin‑sensi-tive protein kinase complex mTORC1 triggered UPR activation in podocytes in an animal model of DN, leading to podocyte injury (60).”
Lipid mediators of insulin signaling in diabetic kidney disease
Mitrofanova, A. V., Sosa, M. A., & Fornoni, A. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00379.2019 · Cited by 32
Maity, S., Das, F., Kasinath, B. S., Ghosh‐Choudhury, N., & Choudhury, G. G. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014994 · Cited by 30
“13) Recently, we and others have shown that mTORC1 controls renal cell pathology in rodent models of fibrosis where TGFβ plays important role (70-76).”
BackgroundPodocyte directed therapy of nephrotic syndrome—can we bring the inside out?
Müller‐Deile, J., & Schiffer, M. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3116-4 · Cited by 31
Bouvier, N., Fougeray, S., Beaune, P. H., Thervet, É., & Pallet, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340570 · Cited by 31
“Therapeutic modulation of the UPRwith 4-phenyl-butyrate or salubrinal can alleviate the deleterious effects of the UPR, reduce kidney injury and delay tissue remodeling (29, 30).”
BackgroundThe regulatory role of miRNA and lncRNA on autophagy in diabetic nephropathy
Yu, S., Li, Y., Lu, X., Han, Z., Li, C., Yuan, X., & Guo, D. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111144 · Cited by 31
Endoplasmic reticulum-mediated organelle crosstalk in kidney disease
Hong, Y. A., & Inagi, R. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00989-4 · Cited by 36
“Similarly, in a mouse model of type 2 DKD, rapamycin reduced BiP accumulation, whereas mTOR activation induced podocyte loss, glomerular membrane thickening and mesangial expansion 235 .”
Das, R., Kim, S., Nguyen, N. T., Kwon, H. J., Cha, S., & Park, K. (2019) · Kidney International · doi:10.1016/j.kint.2019.05.006 · Cited by 30
Podocyte Lysosome Dysfunction in Chronic Glomerular Diseases
Li, G., Kidd, J. M., & Li, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051559 · Cited by 32
“In addition, podocyte-specific mTORC1 activation induced by the ablation of an upstream negative regulator (PcKOTsc1) has been reported to recapitulate many features of DN, including podocyte loss, glomerular basement membrane thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice [120].”
BackgroundEpigenetics and endoplasmic reticulum in podocytopathy during diabetic nephropathy progression
Wang, X., Zhao, J., Li, Y., Rao, J., & Xu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1090989 · Cited by 29
“High glucose induces ER stress, podocyte phenotypic switch, and podocyte loss in rat, effects inhibited by exogenous ER molecular chaperones (60, 61).”
BackgroundEndoplasmic Reticulum Stress in Renal Cell Carcinoma
de Sousa, M. C., Delangre, E., Türkal, M., Foti, M., & Gjorgjieva, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054914 · Cited by 30
“Finally, abnormal activation of the mTOR pathway, which frequently occurs in ccRCC and pRCC, was also shown to ctivate ER stress responses in the kidney, as seen in podocytes in vitro [91].”
BackgroundHamatani, H., Hiromura, K., Sakairi, T., Takahashi, S., Watanabe, M., Maeshima, A., Ohse, T., Pippin, J. W., Shankland, S. J., & Nojima, Y. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00625.2013 · Cited by 30
Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis
Wang, X., Lai, P., Zhang, Z., Huang, M., Wang, L., YIN, M., Jin, D.-D., Zhou, R., & Bai, X. (2014) · Oncology Reports · doi:10.3892/or.2014.3182 · Cited by 29
Nonimmunologic targets of immunosuppressive agents in podocytes
Yoo, T., & Fornoni, A. (2015) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2015.03.003 · Cited by 29
Chen, X., Wang, J., Lin, Y., Liu, Y., & Zhou, T. (2022) · Cells · doi:10.3390/cells11233913 · Cited by 29
“Abnormal activation of mTORC1 leads to mispositioning of the slit diaphragm protein and induces EMT like phenotypic transformation in the presence of increased endoplasmic reticulum stress in the podocytes [68].”
BackgroundSelf-citationTouzot, M., Soulillou, J., & Dantal, J. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32835a4be2 · Cited by 32
Maity, S., Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., & Choudhury, G. G. (2019) · FEBS Letters · doi:10.1002/1873-3468.13505 · Cited by 28
Li, J., Chen, Y., Shen, L., & Deng, Y. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27616 · Cited by 28
“Podocyte dysfunction is postulated to be a critical event associated with proteinuria and glomerulosclerosis in glomerular diseases, including DN.(23) Depletion of glomerular podocytes is an important feature of progressive DN.”
BackgroundPathogenesis of diabesity‐induced kidney disease: role of kidney nutrient sensing
Hinden, L., Kogot‐Levin, A., Tam, J., & Leibowitz, G. (2021) · FEBS Journal · doi:10.1111/febs.15790 · Cited by 30
Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications
Yang, L., Zhang, Z., Wang, D., Jiang, Y., & Liu, Y. (2022) · Current Drug Targets · doi:10.2174/1389450123666220111115528 · Cited by 29
Liu, Y., Long, L., Fang, Y., Liu, F., Liu, H., Peng, Y., Sun, L., & Chen, G. (2014) · Cell Biology International · doi:10.1002/cbin.10363 · Cited by 27
“It is accepted that podocyte injury plays a key role in the process of proteinuria and is associated with DN progression (Inoki et al., 2011; Hara et al., 2012).”
BackgroundLow-Protein Diet for Diabetic Nephropathy
Otoda, T., Kanasaki, K., & Koya, D. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0523-z · Cited by 29
McNicholas, B., Eng, D. G., Lichtnekert, J., Rabinowitz, P. S., Pippin, J. W., & Shankland, S. J. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00196.2016 · Cited by 27
Mavroeidi, V., Petrakis, I., Stylianou, K., Katsarou, T., Giannakakis, K., Perakis, K., Vardaki, E. A., Stratigis, S., Ganotakis, E. S., Papavasiliou, S. S., et al. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413482925 · Cited by 26
“Furthermore, experimental data concerning nephrin protein levels in diabetic nephropathy are conflicting (Inoki et al. 2011).”
BackgroundKitada, M., Ogura, Y., Suzuki, T., Monno, I., Kanasaki, K., Watanabe, A., & Koya, D. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0255-1 · Cited by 28
“Additionally, numerous reports including ours have shown that mTORC1 is activated in diabetic renal cells [19, 20], a process that is closely implicated in the impairment of autophagy [16].”
BackgroundSelf-citationProtective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes
Yoshibayashi, M., Kume, S., Yasuda‒Yamahara, M., Yamahara, K., Takeda, N., Osawa, N., Chin‒Kanasaki, M., Nakae, Y., Yokoi, H., Mukoyama, M., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.088 · Cited by 26
Lysosomal glucose sensing and glycophagy in metabolism
Mancini, M. C., Noland, R. C., Collier, J. J., Burke, S. J., Stadler, K., & Heden, T. D. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.07.008 · Cited by 26
Kleibert, M., Zygmunciak, P., Łakomska, K., Mila, K., Zgliczyński, W., & Mrozikiewicz‐Rakowska, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713038 · Cited by 26
“The process is mediated by TGF-β, which is overexpressed in DKD [108].”
BackgroundInfluential
Metadata
- Authors
- Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., Kwiatkowski, D. J., Rastaldi, M. P., Huber, T. B., Kretzler, M., Holzman, L. B., Wiggins, R. C., & Guan, K.-L.
- Affiliations
- University of Michigan (US)
- Life Sciences Institute (SG)
- University of Basel (CH)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- University of California San Diego (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2181-2196
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104745
- OpenAlex
- W2033798110
- Cited by
- 538
- References
- 77
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 23 · 2023: 36 · 2022: 33 · 2021: 22 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 39 · 2016: 39 · 2015: 35 · 2014: 44 · 2013: 45 · 2012: 36
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- edoc (University of Basel)
- Funders
- National Institutes of Health (5r01dk083491-09, DK083491)
- National Cancer Institute (R01CA108941)
- National Institute of General Medical Sciences (R01GM051586, GM051586)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Oncology › Renal and related cancers
- Keywords
- diabetic nephropathy, mTORC1, podocytes, podocyte loss, proteinuria, glomerulosclerosis, endoplasmic reticulum stress, epithelial-mesenchymal transition, slit diaphragm proteins, TSC1, chemical chaperones, mesangial expansion, glomerular basement membrane thickening
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Tuberous Sclerosis Complex 1 Protein, Animals, Carrier Proteins, Cell Differentiation, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Disease Models, Animal, Endoplasmic Reticulum, Enzyme Activation, Glomerular Mesangium, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Mutant Strains, Phosphorylation, Protein Processing, Post-Translational, Proteins, Mice, Knockout, Ribosomal Protein S6 Kinases, Sirolimus, Tumor Suppressor Proteins, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Glomerular Basement Membrane, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.